(5-Ethylthiophen-3-yl)methanamine | 856696-08-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (5-Ethylthiophen-3-yl)methanamine
• CAS: 856696-08-7
• 化学式: C₇H₁₁NS
• 分子量: 141.237
• InChiKey: QXXXWSZQOSBYKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  54.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (5-Ethylthiophen-3-yl)methanamine 、 methyl 6-[[(1S)-5-cyano-2,3-dihydro-1H-inden-1-yl]carbamoyl]pyrimidine-4-carboxylate 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以28%的产率得到4-N-[(1S)-5-cyano-2,3-dihydro-1H-inden-1-yl]-6-N-[(5-ethylthiophen-3-yl)methyl]pyrimidine-4,6-dicarboxamide
  参考文献：
  名称：

  Multicyclic bis-amide MMP inhibitors

  摘要：

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。

  公开号：

  US20060173183A1
• 作为产物：
  描述：

  5-Ethylthiophene-3-carboxamide 在 tetrabutylammonium borohydride 、 盐酸 、 水 、 氢氧化钾 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 26.0h， 以27%的产率得到(5-Ethylthiophen-3-yl)methanamine
  参考文献：
  名称：

  Substituted bis-amide metalloprotease inhibitors

  摘要：

  这项发明涉及Formula (I)的取代双酰胺嘧啶化合物，这些化合物对于治疗金属蛋白酶介导的疾病，特别是MMP-13相关疾病是有用的。

  公开号：

  US20070155739A1

文献信息

• TRICYCLIC INDOLE HYDROXYETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：GLAXO GROUP LIMITED

  公开号：EP1692143B1

  公开（公告）日：2008-11-12
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Fundación Centro Nacional de Investigaciones Oncologicas Carlos III

  公开号：US20160296528A1

  公开（公告）日：2016-10-13

  There is provided compounds of formula I, wherein R1, R 2a , R 2b , R 2c , X, Y, Z, R 3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.